Dronabinol
| Clinical data | |
|---|---|
| Trade names | Marinol, Syndros | 
| Other names | (−)-trans-Δ9-tetrahydrocannabinol | 
| License data | 
 | 
| Dependence liability | Physical: Low Psychological: Low–moderate | 
| Addiction liability | Relatively low | 
| Routes of administration | By mouth | 
| Drug class | Cannabinoid | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Bioavailability | PO: 6–20% | 
| Onset of action | PO: 0.5–1 hour | 
| Elimination half-life | 25–36 hours | 
| Duration of action | PO: 4–6 hours | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H30O2 | 
| Molar mass | 314.469 g·mol−1 | 
| 3D model (JSmol) | |
| Specific rotation | −152° (ethanol) | 
| Boiling point | 155–157 °C (311–315 °F) 0.05mmHg, 157–160°C @ 0.05mmHg | 
| Solubility in water | 0.0028 mg/mL (23 °C) | 
| 
 | |
| 
 | |
| Part of a series on | 
| Cannabis | 
|---|
Dronabinol (INN), sold under the brand names Marinol and Syndros, is the generic name for the molecule of (−)-trans-Δ9-tetrahydrocannabinol (THC) in the pharmaceutical context. It has indications as an appetite stimulant, antiemetic, and sleep apnea reliever and is approved by the US Food and Drug Administration (FDA) as safe and effective for HIV/AIDS-induced anorexia and chemotherapy-induced nausea and vomiting.
Dronabinol is the principal psychoactive constituent enantiomer form, (−)-trans-Δ9-tetrahydrocannabinol, found in Cannabis sativa L. plants, but can also be synthesized in laboratory. Dronabinol does not include any other tetrahydrocannabinol (THC) isomers or any cannabidiol (CBD).